Rocket Pharmaceuticals(RCKT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress Phase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025 Initial data from the Phase 1 study of RP-A601 for PKP2-ACM anticipated May 2025 IND submission for BAG3-DCM program expected mid-year 2025 Sarbani Chaudhuri appointed Chief Commercial & Medical Af airs Of icer Cash, cash equivalents and investments of approximately $318.2M; expected operational ru ...